RedHill Biopharma (RDHL) Depreciation & Amortization (CF) (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Depreciation & Amortization (CF) data on file, last reported at $491000.0 in Q4 2022.

• On a quarterly basis, Depreciation & Amortization (CF) rose 9.35% year-over-year to $491000.0 in Q4 2022; TTM through Dec 2023 was $491000.0, a 77.01% decrease from a year earlier, with the FY2025 full-year figure at $384000.0, down 34.69% from the prior year.
• Depreciation & Amortization (CF) for Q4 2022 stood at $491000.0, roughly flat from $491000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for RDHL reached as high as $617000.0 in Q2 2022 and fell as low as $22000.0 in Q1 2018.
• Historically, Depreciation & Amortization (CF) has averaged $342350.0 across 5 years, with a median of $433000.0 in 2020.
• Across the five-year window, Depreciation & Amortization (CF) decreased 15.38% in 2018 and surged 1209.09% in 2019, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $23000.0 in 2018, then soared by 1000.0% to $253000.0 in 2019, then surged by 86.96% to $473000.0 in 2020, then fell by 5.07% to $449000.0 in 2021, then rose by 9.35% to $491000.0 in 2022.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $491000.0 in Q4 2022, $491000.0 in Q3 2022, and $617000.0 in Q2 2022.